Pexa-Vec double agent engineered vaccinia: Oncolytic and active immunotherapeutic

Current Opinion in Virology

Volumn 13, Issue , 2015, Pages 49-54

  Breitbach, Caroline J ^a   Parato, Kelley ^b   Burke, James ^a   Hwang, Tae Ho ^c,d   Bell, John C ^b   Kirn, David H ^a  

^a SillaJen Biotherapeutics   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c SillaJen Inc   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEXASTIMOGENE DEVACIREPVEC; ONCOLYTIC VIRUS;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; TRANSGENE; TUMOR IMMUNITY; VACCINIA VIRUS; VIRAL CLEARANCE; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; VIROLOGY;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIRUSES; VACCINIA VIRUS;

EID: 84927699457     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2015.03.016     Document Type: Review

References (50)

1. C. Heise, and D.H. Kirn Replication-selective adenoviruses as oncolytic agents J Clin Invest 105 2000 847 851
2. K.A. Parato, D. Senger, P.A. Forsyth, and J.C. Bell Recent progress in the battle between oncolytic viruses and tumours Nat Rev Cancer 5 2005 965 976
3. D.H. Kirn, and S.H. Thorne Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer Nat Rev Cancer 9 2009 64 71
4. M. Lusky, P. Erbs, J. Foloppe, and R.B. Acres Oncolytic vaccinia virus: a silver bullet? Expert Rev Vaccines 9 2010 1353 1356
5. S.H. Thorne Immunotherapeutic potential of oncolytic vaccinia virus Immunol Res 50 2011 286 293
6. S.H. Thorne Next-generation oncolytic vaccinia vectors Methods Mol Biol 797 2012 205 215
7. R. Vile, and A. Melcher An intravenous stimulus package for oncolytic virotherapy Mol Ther 19 2011 1930 1932
8. K. Guse, V. Cerullo, and A. Hemminki Oncolytic vaccinia virus for the treatment of cancer Expert Opin Biol Ther 11 2011 595 608
9. W.M. Chan, and G. McFadden Oncolytic Poxviruses Ann Rev Virol 1 2014 191 214
10. L.M. Wein, J.T. Wu, and D.H. Kirn Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery Cancer Res 63 2003 1317 1324
11. S.H. Thorne, T.H. Hwang, W.E. O'Gorman, D.L. Bartlett, S. Sei, F. Kanji, C. Brown, J. Werier, J.H. Cho, and D.E. Lee Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 J Clin Invest 117 2007 3350 3358
12. J.H. Kim, J.Y. Oh, B.H. Park, D.E. Lee, J.S. Kim, H.E. Park, M.S. Roh, J.E. Je, J.H. Yoon, and S.H. Thorne Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF Mol Ther 14 2006 361 370
13. J.H. Lee, M.S. Roh, Y.K. Lee, M.K. Kim, J.Y. Han, B.H. Park, P. Trown, D.H. Kirn, and T.H. Hwang Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model Cancer Gene Ther 17 2010 73 79
14. B. Moss Vaccinia virus: a tool for research and vaccine development Science 252 1991 1662 1667
15. E. Quoix, R. Ramlau, V. Westeel, Z. Papai, A. Madroszyk, A. Riviere, P. Koralewski, J.L. Breton, E. Stoelben, and D. Braun Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial Lancet Oncol 12 2011 1125 1133
16. C.E. Gomez, J.L. Najera, M. Krupa, and M. Esteban The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer Curr Gene Ther 8 2008 97 120
17. M.J. Mastrangelo, H.C. Maguire Jr., L.C. Eisenlohr, C.E. Laughlin, C.E. Monken, P.A. McCue, A.J. Kovatich, and E.C. Lattime Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 6 1999 409 422
18. J.M. Burke GM-CSF-armed, replication-competent viruses for cancer Cytokine Growth Factor Rev 21 2010 149 151
19. G. Dranoff GM-CSF-based cancer vaccines Immunol Rev 188 2002 147 154
20. R. Gupta, and L.A. Emens GM-CSF-secreting vaccines for solid tumors: moving forward Discov Med 10 2010 52 60
21. B.H. Park, T. Hwang, T.C. Liu, D.Y. Sze, J.S. Kim, H.C. Kwon, S.Y. Oh, S.Y. Han, J.H. Yoon, and S.H. Hong Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial Lancet Oncol 9 2008 533 542
22. C.J. Breitbach, J. Burke, D. Jonker, J. Stephenson, A.R. Haas, L.Q. Chow, J. Nieva, T.H. Hwang, A. Moon, and R. Patt Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Nature 477 2011 99 102
23. R.M. Eager, C.C. Cunningham, N.N. Senzer, J. Stephenson Jr., S.P. Anthony, S.J. O'Day, G. Frenette, A.C. Pavlick, B. Jones, and M. Uprichard Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma BMC Cancer 9 2009 263
24. J. Heo, T. Reid, L. Ruo, C.J. Breitbach, S. Rose, M. Bloomston, M. Cho, H.Y. Lim, H.C. Chung, and C.W. Kim Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med 19 2013 329 336
25. A.E. Merrick, E.J. Ilett, and A.A. Melcher JX-594, a targeted oncolytic poxvirus for the treatment of cancer Curr Opin Invest Drugs 10 2009 1372 1382
26. T.H. Hwang, A. Moon, J. Burke, A. Ribas, J. Stephenson, C.J. Breitbach, M. Daneshmand, N. De Silva, K. Parato, and J.S. Diallo A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma Mol Ther: J Am Soc Gene Ther 19 2011 1913 1922
27. T.C. Liu, T. Hwang, B.H. Park, J. Bell, and D.H. Kirn The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma Mol Ther 16 2008 1637 1642
28. J. Heo, C.J. Breitbach, A. Moon, C.W. Kim, R. Patt, M.K. Kim, Y.K. Lee, S.Y. Oh, H.Y. Woo, and K. Parato Sequential therapy with JX-594, a targeted oncolytic poxvirus followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy Mol Ther: J Am Soc Gene Ther 19 2011 1170 1179
29. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
30. L. Apetoh, C. Locher, F. Ghiringhelli, G. Kroemer, and L. Zitvogel Harnessing dendritic cells in cancer Sem Immunol 23 2011 42 49
31. C.A. Klebanoff, N. Acquavella, Z. Yu, and N.P. Restifo Therapeutic cancer vaccines: are we there yet? Immunol Rev 239 2011 27 44
32. E.A. Mittendorf, and P. Sharma Mechanisms of T-cell inhibition: implications for cancer immunotherapy Expert Rev Vaccines 9 2010 89 105
33. D.S. Green, M.D. Bodman-Smith, A.G. Dalgleish, and M.D. Fischer Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma Br J Dermatol 156 2007 337 345
34. M.R. Chicoine, M. Zahner, E.K. Won, R.R. Kalra, T. Kitamura, A. Perry, and R. Higashikubo The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4 Neurosurgery 60 2007 372 380 (discussion 381)
35. M.R. Chicoine, E.K. Won, and M.C. Zahner Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme Neurosurgery 48 2001 607 614 (discussion 614-605)
36. K. Furumoto, L. Soares, E.G. Engleman, and M. Merad Induction of potent antitumor immunity by in situ targeting of intratumoral DCs J Clin Invest 113 2004 774 783
37. V. Appay, C. Jandus, V. Voelter, S. Reynard, S.E. Coupland, D. Rimoldi, D. Lienard, P. Guillaume, A.M. Krieg, and J.C. Cerottini New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site J Immunol 177 2006 1670 1678
38. J. Zhu, J. Martinez, X. Huang, and Y. Yang Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta Blood 109 2007 619 625
39. M. Quigley, J. Martinez, X. Huang, and Y. Yang A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection Blood 113 2009 2256 2264
40. J. Martinez, X. Huang, and Y. Yang Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection PLoS Pathog 6 2010 e1000811
41. J. Martinez, X. Huang, and Y. Yang Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA Proc Natl Acad Sci USA 107 2010 6442 6447
42. S.H. Thorne, W. Liang, P. Sampath, T. Schmidt, R. Sikorski, A. Beilhack, and C.H. Contag Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy Mol Ther: J Am Soc Gene Ther 18 2010 1698 1705
43. Y. Yang, C.T. Huang, X. Huang, and D.M. Pardoll Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance Nat Immunol 5 2004 508 515
44. B. Moss Smallpox vaccines: targets of protective immunity Immunol Rev 239 2011 8 26
45. I. Gentschev, M. Muller, M. Adelfinger, S. Weibel, F. Grummt, M. Zimmermann, M. Bitzer, M. Heisig, Q. Zhang, and Y.A. Yu Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68 PLoS One 6 2011 e22069
46. X.Q. Lun, J.H. Jang, N. Tang, H. Deng, R. Head, J.C. Bell, D.F. Stojdl, C.L. Nutt, D.L. Senger, and P.A. Forsyth Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide Clin Cancer Res: Off J Am Assoc Cancer Res 15 2009 2777 2788
47. J.A. McCart, J.M. Ward, J. Lee, Y. Hu, H.R. Alexander, S.K. Libutti, B. Moss, and D.L. Bartlett Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes Cancer Res 61 2001 8751 8757
48. M.K. Kim, C.J. Breitbach, A. Moon, J. Heo, Y.K. Lee, M. Cho, J.W. Lee, S.G. Kim, D.H. Kang, and J.C. Bell Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans Sci Transl Med 5 2013 185ra163
49. D.H. Kirn, Y. Wang, F. Le Boeuf, J. Bell, and S.H. Thorne Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus PLoS Med 4 2007 e353
50. J. Li, M. O'Malley, J. Urban, P. Sampath, Z.S. Guo, P. Kalinski, S.H. Thorne, and D.L. Bartlett Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer Mol Ther: J Am Soc Gene Ther 19 2011 650 657